News
Focusing on innovative 3D cell technology products and services
News
/
News

CDMO of CytoNiche Facilitates Commercialization of Cell Therapy Products | Stem Cell Therapy Products and Services

As cellular drugs are distinct from traditional chemical drugs and biological drugs in terms of process technology, instruments, equipment, and personnel requirements, the CDMO service of cellular dru
31 2022/08

Strategic cooperation | CytoNiche Starts In-depth Cooperation on CDMO Project of Cell Innovation Drugs with Beizheng Stem Cell.

Recently, Beijing CytoNiche Biotechnology Co., Ltd. (hereinafter referred to as CytoNiche) and Jiangxi Beizheng Stem Cell Biotechnology Co., Ltd. (hereinafter referred to as Beizheng Stem Cell) held a strategic cooperation signing ceremony. Through this strategic cooperation, the two parties will make full use of their respective advantages and promote the research and development in the field of large-scale and homogeneous culture of stem cells and clinical application therapy, which is another case for both parties to practice powerful cooperation and innovative development.
30 2022/08

News | CytoNiche Ranked into 36Kr List of Medical Enterprises with 10 Times Growth Potential.

The results of "2022 China's Medical Enterprises with 10 Times Growth Potential" were announced. Beijing CytoNiche Biotechnology Co., Ltd., with its original 3D cell "intelligent" manufacturing techno
25 2022/08

CDMO of CytoNiche Facilitates Commercialization of Cell Therapy Products | Equipment and Consumables for 3D Cell Culture

In the field of stem cell therapy products, at present, cell culture mainly adopts the open production process based on cell culture flasks and multi-layer cell factories. Some enterprises adopt isola
24 2022/08

CytoNiche: New Mode of large-scale Cell Culture CDMO Based on 3D Microcarrier Technology

In August 2022, CytoNiche 3D Cell Intelligent Manufacturing and Regeneration Medical Center—3D FloTrix®Cell CDMO Platform was officially unveiled, adding a new CDMO service platform in the field of ce
23 2022/08

CDMO of CytoNiche Facilitates Commercialization of Cell Therapy Products | GMP Production Environment of Cells

Different from most small molecule drugs and many biological drugs, the main forms of CGT products include gene therapy vectors, oncolytic virus products, cell products (such as CAR-T, NK cells, stem
19 2022/08
Previous page
1
2
3
4
5
6
Copyright: Beijing CytoNiche Biotechnology Co., Ltd.
Copyright: Beijing CytoNiche Biotechnology Co., Ltd.